![]() |
JOURNAL TOOLS |
eTOC |
To subscribe |
Submit an article |
Recommend to your librarian |
ARTICLE TOOLS |
Reprints |
Permissions |

YOUR ACCOUNT
YOUR ORDERS
SHOPPING BASKET
Items: 0
Total amount: € 0,00
HOW TO ORDER
YOUR SUBSCRIPTIONS
YOUR ARTICLES
YOUR EBOOKS
COUPON
ACCESSIBILITY
Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis OVARIAN CANCER
Minerva Medica 2009 October;100(5):371-83
Copyright © 2009 EDIZIONI MINERVA MEDICA
language: English
Decisions and ethical issues among BRCA carriers and the use of preimplantation genetic diagnosis
Quinn G. P. 1, 2, Vadaparampil S. T. 1, 2, Bower B. 1, Friedman S. 3, Keefe D. L. 4 ✉
1 Moffitt Cancer Center and Research Institute, Division of Cancer Prevention and Control, Tampa, FL, USA; 2 University of South Florida College of Medicine, Department of Oncologic Science, Tampa, FL, USA; 3 FORCE: Facing Our Risk of Cancer Empowered, Tampa, FL, USA; 4 University of South Florida, College of Medicine, Department of Obstetrics and Gynecology, Tampa, FL, USA
The lifetime risks for both breast and ovarian cancer for BRCA mutation carriers far exceeds the general population risk of 13% for breast cancer and 1.4% for ovarian cancer. BRCA carriers have unique and medically complicated decisions to make regarding their cancer treatment or risk reduction. As BRCA testing becomes increasingly common among unaffected individuals in families with a previously documented BRCA mutation, there are a growing number of individuals with unique psychosocial needs and concerns. This review paper describes the BRCA 1/2 population, discusses preimplantation genetic diagnosis (PGD), and describes the decisions and ethical issues related to PGD among the BRCA 1/ 2 population.